Skip to main content
OpenTrials
Completed

NCT Number: NCT02875717

Influence of Acetylsalicylic Acid and Low Molecular Weight Heparins on the Incidence of Renal Hematoma of Shockwave Lithotripsy

Retrospective Analysis of patients that received shockwave lithotripsy as Treatment of ureteral or kidney Stones. Condition examinated is the effect of low molecular weight Heparins and acetylsalicylic acid on the Formation of renal hematoma after shockwave lithotripsy. Primary outcome is documented hematoma in a postoperative ultrasound control. Secondary outcomes are perioperative complication, Need for erythrocyte tranfusion, interventions for bleeding control, readmission or death within 30 days.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Urolithiasis Female Urogenital Diseases Female Urogenital Diseases and Pregnancy Complications Male Urogenital Diseases Renal Hematoma Urogenital Diseases Urologic Diseases

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Kantonsspital Winterthur

Winterhur, Canton of Zurich, 8401, Switzerland

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • consent
  • Stones in kidney and proximal Ureter
  • Treatment with shockwave lithotripsy for urolithiasis between January 2009 and September 2015 at Kantonsspital Winterthur

Exclusion criteria

  • other Position of ureteral Stones
  • missing data in Patient reports
  • refused consent
  • under Age limit

Treatment and study plan

acetylsalicylic acid

Drug

Low molecular weight heparin

Drug

Primary outcomes

  1. Renal Hematoma in ultrasound control

    Time frame: first day after intervention

Secondary outcomes

  1. Intervention for bleeding control

    Time frame: 30 days after intervention

  2. Need for erythrocyte concentrate tranfusion

    Time frame: 30 days after intervention

  3. Death

    Time frame: 30 days after intervention

  4. Hospital readmission

    Time frame: 30 days after intervention

Sponsors and collaborators

Lead sponsor

Kantonsspital Winterthur KSW

Other

Registry information

Important dates

Study start
2009
Primary completion
2015
Study completion
2015
First posted
Aug 23, 2016
Registry last updated
Aug 23, 2016

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.